OIPE JC17
MAY 2 8 2004
U.S. PATENT & TRADEMARK OFFICE

MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1

Complete if Known	
Application Number	10/684,746
Confirmation Number	4047
Filing Date	October 15, 2003
First Named Inventor	Ravi V. J. CHARI
Art Unit	1626
Examiner Name	A. Small (in parent)
Attorney Docket Number	A8658

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number	Document Number: Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
RS		US 6,340,701	B1	01-22-2002	Chari, *et al.*

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Foreign Patent Document: Number[4]	Foreign Patent Document: Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation[6]

Examiner Signature		Date Considered	9/21/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	DIV of 10/207,814
	Confirmation Number	3691 (in parent)
	Filing Date	
	First Named Inventor	Ravi V. J. CHARI
(use as many sheets as necessary)	Art Unit	1626 (in parent)
	Examiner Name	A. Small (in parent)
Sheet 1 of 1	Attorney Docket Number	A8658

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
RL		6,175,023	01-2001	Lui	—	—	
RL		5,824,701	10-1998	Greenwald	—	—	
RL		5,475,092	12/12/95	Chari	—	—	
RL		5,416,064	05/16/95	Chari	—	—	
RL		5,475,011	12/12/95	Ojima	—	—	
RL		5,811,452	09/22/98	Ojima	—	—	
RL		5,399,726	03/21/95	Holton	—	—	

FOREIGN PATENT DOCUMENTS

		Document	Date	Country	Class	Sub-class	Translation Yes/No
RL	WO	00/50059	08/31/00	PCT	—	—	
RL	WO	97/44026	11/27/97	PCT	—	—	
RL	WO	98/52614	11/26/98	PCT	—	—	
RL	WO	89/12624	12/28/89	PCT	—	—	
RL	WO	98/19705	05/14/98	PCT	—	—	
RL	EP	1033372	09/06/00	EPO	—	—	
RL	EP	0624377	05/13/94	EPO	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RL		Safavy et al, *J. Med. Chem.*, 42:4919-4924 (1999)
RL		American Chemical Society Division of Medicinal Chemistry, Abstracts, 218th ACS National Meeting, New Orleans, LA, August 22-26, 1999, A. Trainor, Program Chair
RL		Synthesis and Biological Activity of Advanced 2nd-Generation Taxoids, Tao Wang et al, Dept. of Chem., State Univ. of NY at Stony Brook, NY 11794-3400; Dept. of Exp. Therapeutics, Roswell Park Cancer Inst., Elm and Carlton Streets, Buffalo, NY 14263, pages 1-12
RL		Ojima et al, *J. Med. Chem.*, 40:267-278 (1997)
RL		Ojima et al, *Proc. Natl. Acad. Sci., USA*, 96:4256-4261 (1999)

EXAMINER: [signature] DATE CONSIDERED: 9/21/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.